Log in to search using one of your social media accounts:

 

Cells from Diseased Donors
Focus on Neuro Diseases We now have the capability to provide cells of the central and peripheral nervous system from donors with Neuro diseases. These include cells from donors with ALS, AD, PD, and Brain Cancer Donors, to name a few.We have provided cells to virtually all the large Pharmas and many small and mid-size Bio-techs. We have worked with Novartis to gain 21-CFR compliance for cells that they are using for their eye diseases drug discovery programs.I am at your “beck and call” should you have interested in exploring specific capabilities further. You can e-mail or call me at 612-801-1007 (Source: Neuromics)
Source: Neuromics - January 15, 2018 Category: Neuroscience Tags: 3-D Cell based Assays ALS Alzheimer ' s Disease Amyotrophic Lateral Sclerosis glioblastomas Parkinson Source Type: news

Cellular traffic jam seen in ALS/FTD -- Supports drug strategy
(Emory Health Sciences) A cellular traffic jam appears to affect neurons in most forms of ALS (amyotrophic lateral sclerosis), Emory/Mayo researchers have shown. The findings suggest that a drug strategy aimed at easing the traffic jam may be generalizable to sporadic and at least some familial types of ALS and FTD (frontotemporal dementia). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 8, 2018 Category: International Medicine & Public Health Source Type: news

Understanding the molecular mechanisms of ALS
(Hokkaido University) Scientists have revealed more details of the molecular mechanism behind neuronal cell death in amyotrophic lateral sclerosis (ALS), a step forward to find ways to control progression of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 26, 2017 Category: International Medicine & Public Health Source Type: news

CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - December 21, 2017 Category: American Health Source Type: news

Disarm Therapeutics Appoints Peter Keller Chief Business Officer
CAMBRIDGE, Mass., Dec. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological diseas... Biopharmaceuticals, Neurology, Personnel Disarm Therapeutics, SARM1, multiple sclerosis, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 19, 2017 Category: Pharmaceuticals Source Type: news

Upsized $300M biotech IPO could be huge — or another flop in Alzheimer’s and ALS
There's a lot riding on Denali Therapeutics Inc.'s upsized, mountainous $303 million IPO — and it goes beyond the eye-popping fundraise. To be sure, investors are watching the South San Francisco developer of drugs for Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis, or ALS — in a Securities and Exchange Commission filing Thursday morning, the 125-employe e company boosted the shares available in the IPO from 9.58 million to 15.97 million. At the top of its $17 to… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 7, 2017 Category: American Health Authors: Ron Leuty Source Type: news

Why this $300 million biotech IPO could be huge — or another flop in Alzheimer’s and ALS
There's a lot riding on Denali Therapeutics Inc.'s upsized, mountainous $303 million IPO — and it goes beyond the eye-popping fundraise. To be sure, investors are watching the South San Francisco developer of drugs for Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis, or ALS — in a Securities and Exchange Commission filing Thursday morning, the 125-employe e company boosted the shares available in the IPO from 9.58 million to 15.97 million. At the top of its $17 to… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 7, 2017 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

The MNI forms promising Open Science partnership with Takeda
(McGill University) A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2017 Category: International Medicine & Public Health Source Type: news

Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA(R) (edaravone) to U.S. Department of Veterans Affairs National Formulary
JERSEY CITY, N.J., Nov. 30, 2017 -- (Healthcare Sales & Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced today that the U.S. Department of Veterans Affairs (VA) has added RADICAVA® (edaravone) to its National Formulary (VA... Biopharmaceuticals, Neurology, Reimbursement Mitsubishi Tanabe Pharma, RADICAVA, edaravone, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 30, 2017 Category: Pharmaceuticals Source Type: news

Barrow researchers validate five new genes responsible for ALS
(St. Joseph's Hospital and Medical Center) Barrow Neurological Institute researchers have completed additional experiments that validate the identification of five new genes linked to Amyotrophic Lateral Sclerosis (ALS) -- also known as Lou Gehrig's disease. The new study results, validated through five different methods, were published in a full length manuscript in Acta Neuropathologica, validating earlier findings in the project. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 30, 2017 Category: Biology Source Type: news

Swinging at Lou Gehrig's disease, Peninsula drug maker strikes out
After spending "hundreds of millions" of dollars over eight years on an experimental drug for people with amyotrophic lateral sclerosis, or ALS, a South San Francisco company's late-stage trial came up short. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 21, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

Swinging at Lou Gehrig's disease, Peninsula drug maker strikes out
After spending "hundreds of millions" of dollars over eight years on an experimental drug for people with amyotrophic lateral sclerosis, or ALS, a South San Francisco company's late-stage trial came up short. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - November 21, 2017 Category: Health Management Authors: Ron Leuty Source Type: news

Swinging at Lou Gehrig's disease, Peninsula drug maker strikes out
After spending "hundreds of millions" of dollars over eight years on an experimental drug for people with amyotrophic lateral sclerosis, or ALS, a South San Francisco company's late-stage trial came up short. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 21, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

Cytokinetics ALS Drug Fails
Cytokinetics, a biotechnology company, had hoped that by focusing on improving the function of muscle, not nerves, it could have an impact on lung function in patients with amyotrophic lateral sclerosis, popularly known as Lou Gehrig's disease, a nerve-destroying disorder. It didn't work. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 21, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news

Discovery of a promising medication for amyotrophic lateral sclerosis (ALS)
Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that could make it possible to treat individuals with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. An article published today in JCI Insight concludes that pimozide was found to be safe and over the short term, preliminary data shows that it could stabilize the progression of ALS. (Source: World Pharma News)
Source: World Pharma News - November 16, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Trauma and amyotrophic lateral sclerosis: a European population-based case-control study from the EURALS consortium - Pupillo E, Poloni M, Bianchi E, Giussani G, Logroscino G, Zoccolella S, Chio A, Calvo A, Corbo M, Lunetta C, Marin B, Mitchell D, Hardiman O, Rooney J, Stevic Z, Bandettini di Poggio M, Filosto M, Cotelli MS, Perini M, Riva N, Tremolizzo L, Vitelli E, Damiani D, Beghi E.
OBJECTIVES: To assess the association between amyotrophic lateral sclerosis (ALS) and previous traumatic events, age of trauma, and site of injury. METHODS: A population-based case-control study was performed in five European countries (Italy, Irel... (Source: SafetyLit)
Source: SafetyLit - October 30, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Meta-analytic evaluation of the association between head injury and risk of amyotrophic lateral sclerosis - Watanabe Y, Watanabe T.
Head injury is considered as a potential risk factor for amyotrophic lateral sclerosis (ALS). However, several recent studies have suggested that head injury is not a cause, but a consequence of latent ALS. We aimed to evaluate such a possibility of revers... (Source: SafetyLit)
Source: SafetyLit - October 30, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

BrainStorm enrolls first ALS patient in late-stage NurOwn trial
Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that the first patients have been enrolled in its Phase III trial evaluating NurOwn as a treatment for amyotrophic lateral sclerosis, or ALS, at Massachusetts General Hospital and UC Irvine Medical Center. The trial, which is slated to enroll 200 patients, is designed to include the pre-specified patient subgroups who saw superior outcomes in the NurOwn Phase II ALS trial. BrainStorm said it expects top-line data from the trial in 2019. Get the full story at our sister site, Drug Delivery Business News. The post BrainStorm enrolls first ALS patient in late-stage NurO...
Source: Mass Device - October 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Neurological Stem Cells Wall Street Beat BrainStorm Cell Therapeutics Inc. Source Type: news

BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn(R) in ALS
Trial supported by a $16M non-dilutive grant from CIRM Top-line data are expected in 2019 HACKENSACK, N.J. and PETACH TIKVA, Israel, Oct. 16, 2017 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today an... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 16, 2017 Category: Pharmaceuticals Source Type: news

The eyes have it: how technology allows you to speak when all you can do is blink
Developments in eye-gaze technology – which converts minute movements of the eye into spoken words – are opening up undreamed of opportunities for people with motor neurone syndromeSteve Thomas and I are talking about brain implants. Bonnie Tyler ’s Holding Out For a Hero is playing in the background and for a moment I almost forget that a disease has robbed Steve of his speech. The conversation breaks briefly; now I see his wheelchair, his ventilator, his hospital bed.Steve, a software engineer, was diagnosed with ALS (amyotrophic lateral sclerosis, a type ofmotor neurone disease) aged 50. He knew i...
Source: Guardian Unlimited Science - October 16, 2017 Category: Science Authors: Jules Montague Tags: Motor neurone disease Medical research Technology Society Science Health & wellbeing Life and style Source Type: news

BrainStorm enrolls first patients in advanced ALS stem cell trial
TEL AVIV (Reuters) - BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Masitinib Added to Riluzole Slows Progression of ALS Masitinib Added to Riluzole Slows Progression of ALS
A study shows a beneficial effect of adding masitinib to riluzole for the treatment of amyotrophic lateral sclerosis. Compared with placebo, masitinib slowed disease progression and prolonged survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Same mainstream media attacking football as "unsafe for the brain" says nothing about brain-damaging mercury in vaccines
(Natural News) Football is suddenly facing a tremendous amount of scrutiny for its potential to cause irreparable damage to players. While any number of injuries are associated with such a heavy-duty contact sport, football stands alone in its potential for irreversible brain damage; many players have suffered from traumatic brain injuries, concussions, amyotrophic lateral sclerosis (ALS,... (Source: NaturalNews.com)
Source: NaturalNews.com - September 17, 2017 Category: Consumer Health News Source Type: news

New ALS drug Radicava comes with new questions as well
It is the first new drug for amyotrophic lateral sclerosis in 22 years. (Source: ABC News: Health)
Source: ABC News: Health - August 10, 2017 Category: Consumer Health News Tags: Health Source Type: news

Amylyx begins dosing in Phase II trial of AMX0035 for ALS
Amylyx Pharmaceuticals has begun dosing patients in the Phase II CENTAUR clinical trial of its therapeutic candidate, AMX0035, to treat those with amyotrophic lateral sclerosis (ALS). (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news

Tiny Cambridge startup backed by Termeer launches trial of ALS drug
A tiny Cambridge startup backed by the late Henri Termeer has reached an important milestone in its quest to develop a more effective treatment for amyotrophic lateral sclerosis, the debilitating neurological disorder known as ALS. Amylyx Pharmaceuticals, a largely virtual biotech that was founded in 2013 and has just three full-time employees, said Tuesday that it had dosed the first patient in a Phase 2 study of its drug, called AMX0035. Termeer, the founder of Genzyme, was a board member and… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 8, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.
RADICAVA™ (edaravone) Indicated for All Adult Patients Diagnosed with ALS JERSEY CITY, N.J., Aug. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therap... Biopharmaceuticals, Neurology, Product Launch Mitsubishi Tanabe Pharma, RADICAVA, edaravone, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 8, 2017 Category: Pharmaceuticals Source Type: news

BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
Mary Kay Turner brings 25+ years Biotech and Pharmaceutical Experience in Healthcare Advocacy and Policy; Prior Positions Include Head of Patient Advocacy and Communications at Mitsubishi Tanabe Pharma America and Head of State Government Affairs and Advoc... Regenerative Medicine, Neurology, Personnel BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 7, 2017 Category: Pharmaceuticals Source Type: news

$3.2M grant to The Jackson Laboratory for study of new ALS candidate gene
(Jackson Laboratory) A new five-year federal research grant totaling $3,322,009 to The Jackson Laboratory (JAX) will fund studies of a new mouse model for amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2017 Category: International Medicine & Public Health Source Type: news

$3.2 million grant to The Jackson Laboratory for study of new ALS candidate gene
(Jackson Laboratory) A new five-year federal research grant totaling $3,322,009 to The Jackson Laboratory (JAX) will fund studies of a new mouse model for amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2017 Category: International Medicine & Public Health Source Type: news

Flex Pharma begins Phase II trial of FLX-787 for ALS in US
Flex Pharma has begun a Phase II clinical trial (COMMEND) of FLX-787 in the US to treat patients suffering from motor neuron disease (MND) with a focus on amyotrophic lateral sclerosis (ALS). (Source: Drug Development Technology)
Source: Drug Development Technology - August 2, 2017 Category: Pharmaceuticals Source Type: news

Cytokinetics evaluates CK-2127107 in Phase II trial to treat ALS
US-based Cytokinetics has started a Phase II FORTITUDE-ALS clinical trial of CK-2127107 for the treatment of patients with amyotrophic lateral sclerosis (ALS). (Source: Drug Development Technology)
Source: Drug Development Technology - July 30, 2017 Category: Pharmaceuticals Source Type: news

UCLA researchers reveal unusual chemistry of protein with role in neurodegenerative disorders
A common feature of neurodegenerative diseases is the formation of permanent tangles of insoluble proteins in cells. The beta-amyloid plaques found in people with Alzheimer ’s disease and the inclusion bodies in motor neurons in the brains of people with amyotrophic lateral sclerosis are two examples. Those aggregates, and others like them, can kill cells and lead to debilitating and progressive neurodegenerative diseases.A study by Douglas Black and colleagues in UCLA ’s department of microbiology, immunology and molecular genetics, reveals that not all protein aggregates in brain cells are toxic. Their paper,...
Source: UCLA Newsroom: Health Sciences - July 26, 2017 Category: Universities & Medical Training Source Type: news

Brainstorm adds UCal Irvine Medical Center to late-stage NurOwn trial
Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it inked an agreement with the University of California Irvine Medical Center to enroll patients in the Phase III trial of its NurOwn mesenchymal stem cell-based platform for amyotrophic lateral sclerosis. This marks the third medical center to work with Brainstorm to enroll patients in the late-stage pivotal trial. The company said last week that Massachusetts General Hospital and California Pacific Medical Center both agreed to participate in the trial. Get the full story at our sister site, Drug Delivery Business News. The post Brainstorm adds UCal Irvine Med...
Source: Mass Device - July 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Regenerative Medicine Stem Cells Wall Street Beat BrainStorm Cell Therapeutics Inc. Source Type: news

BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 25, 2017 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced tha... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2017 Category: Pharmaceuticals Source Type: news

Brainstorm Cell Therapeutics wins $16m grant for pivotal NurOwn ALS study
Brainstorm Cell Therapeutics (NSDQ:BCLI) said today it won a $16 million grant from the California Institute of Regenerative Medicine to engage in a phase 3 study of its NurOwn mesenchymal stem cell-based platform for treating amyotrophic lateral sclerosis. Brainstorm said it is in the advanced stages of planning a Phase 3 clinical trial investigating NurOwn for treating ALS. The trial is slated to enroll approximately 200 patients at 6 sites in the US, with the primary outcome being an ALSFR-S score responder analysis. Read the whole story on our sister site, Drug Delivery Business The post Brainstorm Cell Therapeuti...
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Clinical Trials Regenerative Medicine BrainStorm Cell Therapeutics Inc. Source Type: news

Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn(R) in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 21, 2017 -- (Healthcare Sales & Marketing Network) -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced tha... Regenerative Medicine, Neurology Brainstorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 21, 2017 Category: Pharmaceuticals Source Type: news

BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 18, 2017 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced tha... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 18, 2017 Category: Pharmaceuticals Source Type: news

Mortality from Amyotrophic Lateral Sclerosis and Parkinson's Disease Among Different Occupation Groups - United States, 1985-2011
CDC evaluated associations between usual occupation and ALS and Parkinson's disease mortality using data from CDC's National Institute for Occupational Safety and Health (NIOSH) National Occupational Mortality Surveillance (NOMS). (Source: HSR Information Central)
Source: HSR Information Central - July 18, 2017 Category: International Medicine & Public Health Source Type: news

Mortality from Amyotrophic Lateral Sclerosis and Parkinson ’s Disease Among Different Occupation Groups - United States, 1985-2011
CDC evaluated associations between usual occupation and ALS and Parkinson's disease mortality using data from CDC's National Institute for Occupational Safety and Health (NIOSH) National Occupational Mortality Surveillance (NOMS). (Source: PHPartners.org)
Source: PHPartners.org - July 18, 2017 Category: International Medicine & Public Health Source Type: news

White Collar Workers At Higher Odds of Death from ALS, Parkinson's
Study found richer, better-educated folks with these brain diseases are more likely to die Source: HealthDay Related MedlinePlus Pages: Amyotrophic Lateral Sclerosis, Parkinson's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 13, 2017 Category: Consumer Health News Source Type: news

Mortality from Amyotrophic Lateral Sclerosis and Parkinson ’s Disease Among Different Occupation Groups — United States, 1985–2011
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 13, 2017 Category: American Health Source Type: news

Creating music by thought alone
(Frontiers) Neurologists have created a hands-free, thought-controlled musical instrument, which they've recently described in a report in Frontiers in Human Neuroscience. Researchers hope that this new instrument will help empower and rehabilitate patients with motor disabilities such as those from stroke, spinal cord injury, amputation, or amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 12, 2017 Category: International Medicine & Public Health Source Type: news

Rogue genes may cause some ALS cases
Gene mutations may cause up to 17 percent of cases of amyotrophic lateral sclerosis (ALS) in patients with no family history of the disease, a new study finds. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 22, 2017 Category: Consumer Health News Source Type: news

Rogue Genes May Cause Some ALS Cases
Most people with Lou Gehrig's disease have no known family history of it Source: HealthDay Related MedlinePlus Pages: Amyotrophic Lateral Sclerosis, Genes and Gene Therapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 21, 2017 Category: Consumer Health News Source Type: news

Rogue Genes May Cause Some ALS Cases
WEDNESDAY, June 21, 2017 -- Gene mutations may cause up to 17 percent of cases of amyotrophic lateral sclerosis (ALS) in patients with no family history of the disease, a new study finds. ALS, often referred to as Lou Gehrig's disease, is a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 21, 2017 Category: General Medicine Source Type: news

Scripps Research Institute scores $7M grant to cure ALS
A professor with the Jupiter outpost of the Scripps Research Institute has received a grant of more than $7 million to create new treatments for amyotrophic lateral sclerosis (ALS), the neurological disease that earned widespread national attention when the “ice bucket challenge” went viral on social media in 2014. Professor Matthew Disney, of Scripps' Department of Chemistry, was awarded $7.2 million from the National Institute of Neurological Disorders and Stroke of the National Institutes… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 19, 2017 Category: American Health Authors: Debora Lima Source Type: news

Scripps Florida scientist and collaborators win $7 million grant to develop new ALS treatments
(Scripps Research Institute) Professor Matthew Disney of the Department of Chemistry on the Florida campus of The Scripps Research Institute (TSRI), together with scientists from Mayo Clinic's Florida campus and Johns Hopkins School of Medicine, has been awarded $7.2 million from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health to create new RNA-based treatments for the most common form of amyotrophic lateral sclerosis (ALS), as well as a type of frontotemporal dementia (FTD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2017 Category: International Medicine & Public Health Source Type: news

6 Ways To Survive Summer Travel With A Chronic Illness
Two summers ago, I planned the family road trip of a lifetime. I bought an inexpensive and used camping trailer, loaded it up with everything from toiletries to food, and set out on a 21-day road trip through six western states. I planned our route meticulously, lining up activities and stops along the way, but what got lost in the shuffle was my own chronic health needs. I assumed I would be able to stretch out my regular medical infusions to allow for my travel or refill my prescriptions on-the-go, but I quickly learned how wrong I was. I spent way too much of my vacation tackling my medical challenges instead of enjoyin...
Source: Healthy Living - The Huffington Post - June 14, 2017 Category: Consumer Health News Source Type: news